OpenURL Connection Search

Select item for more details and to access through your institution.

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol.
Published in:
BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12336-0
By:
- Janssen, J. C.;
- van Dijk, B.;
- de Joode, K.;
- Aarts, M. J. B.;
- van den Berkmortel, F. W. P. J.;
- Blank, C. U.;
- Boers-Sonderen, M. J.;
- van den Eertwegh, A. J. M.;
- de Groot, J. W. B.;
- Jalving, M.;
- de Jonge, M. J. A.;
- Joosse, A.;
- Kapiteijn, E.;
- Kamphuis-Huismans, A. M.;
- Naipal, K. A. T.;
- Piersma, D.;
- Rikhof, B.;
- Westgeest, H. M.;
- Vreugdenhil, G.;
- Oomen-de Hoop, E.
Publication type:
Article
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Published in:
2021
By:
- Mulder, E. E. A. P.;
- de Joode, K.;
- Litière, S.;
- ten Tije, A. J.;
- Suijkerbuijk, K. P. M.;
- Boers-Sonderen, M. J.;
- Hospers, G. A. P.;
- de Groot, J. W. B.;
- van den Eertwegh, A. J. M.;
- Aarts, M. J. B.;
- Piersma, D.;
- van Rijn, R. S.;
- Kapiteijn, E.;
- Vreugdenhil, G.;
- van den Berkmortel, F. W. P. J.;
- Hoop, E. Oomen-de;
- Franken, M. G.;
- Ryll, B.;
- Rutkowski, P.;
- Sleijfer, S.
Publication type:
journal article
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
Published in:
British Journal of Cancer, 2014, v. 110, n. 4, p. 888, doi. 10.1038/bjc.2013.798
By:
- Hamberg, P;
- Boers-Sonderen, M J;
- van der Graaf, W T A;
- de Bruijn, P;
- Suttle, A B;
- Eskens, F A L M;
- Verweij, J;
- van Herpen, C M L;
- Sleijfer, S
Publication type:
Article
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
Published in:
Acta Oncologica, 2021, v. 60, n. 1, p. 69, doi. 10.1080/0284186X.2020.1818823
By:
- Boekhout, A. H.;
- Rogiers, A.;
- Jozwiak, K.;
- Boers-Sonderen, M. J.;
- van den Eertwegh, A. J.;
- Hospers, G. A.;
- de Groot, J. W. B.;
- Aarts, M. J. B.;
- Kapiteijn, E.;
- ten Tije, A. J.;
- Piersma, D.;
- Vreugdenhil, G.;
- van der Veldt, A. A.;
- Suijkerbuijk, K. P. M.;
- Rozeman, E. A.;
- Neyns, B.;
- Janssen, K. J.;
- van de Poll-Franse, L. V.;
- Blank, C. U.
Publication type:
Article
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Published in:
2013
By:
- Boers-Sonderen, M. J.;
- Desar, I. M. E.;
- Koopman, M.;
- Punt, C. J.;
- van Herpen, C. M. L.
Publication type:
Letter
Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
Published in:
Quality of Life Research, 2023, v. 32, n. 9, p. 2517, doi. 10.1007/s11136-023-03427-9
By:
- Egeler, M. D.;
- van de Poll-Franse, L. V.;
- Tissier, R.;
- Rogiers, A.;
- Boers-Sonderen, M. J.;
- van den Eertwegh, A. J.;
- Hospers, G. A.;
- de Groot, J. W. B.;
- Aarts, M. J. B.;
- Kapiteijn, E.;
- Piersma, D.;
- Vreugdenhil, G.;
- van der Veldt, A. A.;
- Suijkerbuijk, K. P. M.;
- Neyns, B.;
- Janssen, K. J.;
- Blank, C. U.;
- Retèl, V. P.;
- Boekhout, A. H.
Publication type:
Article
Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.
Published in:
Pigment Cell & Melanoma Research, 2024, v. 37, n. 1, p. 15, doi. 10.1111/pcmr.13117
By:
- Borgers, J. S. W.;
- Burgers, F. H.;
- Schina, A.;
- Van Not, O. J.;
- van den Eertwegh, A. J. M.;
- Blank, C. U.;
- Aarts, M. J. B.;
- van den Berkmortel, F. W. P. J.;
- de Groot, J. W. B.;
- Hospers, G. A. P.;
- Kapiteijn, E.;
- Piersma, D.;
- van Rijn, R. S.;
- Boer, A. M. Stevense‐den;
- van der Veldt, A. A. M.;
- Vreugdenhil, G.;
- Boers‐Sonderen, M. J.;
- Wouters, M. W. J. M.;
- Suijkerbuijk, K. P. M.;
- van Thienen, J. V.
Publication type:
Article

Found: 7

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol.

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.

Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.